Need Help?
Copied to clipboard!

Epigenome-informed deep learning identifies tumor-derived cfDNA fragments and improves liquid biopsy diagnostics in the absence of genetic aberrations

Liquid biopsy holds great promise for cancer diagnosis and therapy guidance. However, the low mutational bur-den of many pediatric tumors poses challenges to the detection of circulating tumor DNA (ctDNA). Here we present DEFT, a high-resolution multimodal deep learning method for ctDNA detection that does not depend on genetic aberrations. DEFT predicts which cell-free DNA (cfDNA) fragments are tumor-derived, based on the integration of DNA methylation, cfDNA fragmentation, and genomic properties. DEFT’s fragment-level prediction unlocks ample training data for deep learning even among small cohorts, and enables head-to-head comparisons between tumor-derived and healthy-derived cfDNA fragments from the same patient for investigating cfDNA biology. We combined DEFT with a DNA methylation assay that conserves cfDNA fragmentation, reaching 96% and 90% sensitivity for detection of Ewing sarcoma at 95% specificity across 335 individuals in two multinational clinical trial cohorts. In summary, we present a new method for deep learning based cfDNA analysis and demonstrate its utility by developing liquid biopsy assays for diagnosing and monitoring pediatric tumors.

Cite

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000003205 Illumina NovaSeq 6000 318